Christopher Lebo, DO
Family Medicine · Somerset, MANPI 1477558823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$859
- Novo Nordisk$647
- Johnson & Johnson$555
- Lilly USA, LLC$387
- AstraZeneca$371
- Boehringer Ingelheim$345
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,13098%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 61 | $859 |
| Novo Nordisk | 39 | $647 |
| Johnson & Johnson | 33 | $555 |
| Lilly USA, LLC | 25 | $387 |
| AstraZeneca | 18 | $371 |
| Boehringer Ingelheim | 15 | $345 |
| Nestle Healthcare Nutrition Inc. | 10 | $211 |
| Amgen | 10 | $200 |
| Sunovion Pharmaceuticals Inc. | 9 | $173 |
| Paratek Pharmaceuticals, Inc. | 5 | $138 |
| Bayer | 7 | $137 |
| Astellas Pharma US Inc | 8 | $137 |
| AbbVie(2 entities) | 8 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $116 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
| Merck | 7 | $111 |
| Novartis | 4 | $85 |
| Amarin Pharma, Inc. | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Mylan Specialty L.p. | 3 | $45 |
| GSK | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Abbott | 2 | $42 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Gilead | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Zimmer Biomet | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$5,245 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 355 | $100,634 |
| XifaxanRifaximin | 15 | $37,889 |
| JardianceEmpagliflozin | 98 | $30,756 |
| AustedoDeutetrabenazine | 21 | $18,608 |
| OzempicSemaglutide | 18 | $18,301 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $11,604 |
| TradjentaLinagliptin | 42 | $10,803 |
| FarxigaDapagliflozin Propanediol | 38 | $10,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,493 |
| CreonLipase/Protease/Amylase | 13 | $10,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,079 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 27 | $8,032 |
| ErtapenemErtapenem Sodium | 15 | $7,134 |
| Potassium Chloride | 297 | $6,753 |
| Rasagiline Mesylate | 25 | $6,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $859 | $100,634355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $345 | $41,559140 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $116 | $37,88915 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $43 | $26,60459 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $65 | $18,60821 claims |
| Novo NordiskOzempic | $647 | $18,30118 claims |
| AstraZenecaFarxiga | $371 | $10,75538 claims |
| AbbVieCreon | $129 | $10,48613 claims |
| Johnson & JohnsonXarelto | $555 | $3,42712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Somerset
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Sanjeev SharmaFramingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.